Spotlight on Mebendazole

Mechanisms of Action

• Microtubule Disruption: Binds to β-tubulin, disrupting microtubule assembly, leading to G2/M mitotic arrest and apoptosis in cancer cells.
• Inhibition of Cancer Stem Cells (CSCs): Decreases Hedgehog and Wnt pathway signaling crucial to CSC self-renewal and tumor propagation.
• Anti-angiogenic Activity: Inhibits vascular endothelial growth factor receptor-2 (VEGFR2), preventing tumor-driven blood vessel formation.
• Induction of Apoptosis & Autophagy: Triggers caspase activation, mitochondrial dysfunction, and programed cell death.
• Downregulation of Oncogenic Pathways: Suppresses Bcl-2, c-Myc, MAPK, and STAT3 pathways, hindering cancer proliferation and metastasis.
• Immune Modulation: Potentiates immune responses, enhancing cytotoxic T-cell activity and modulating proinflammatory cytokines.

Clinical Evidence

• Pancreatic Cancer: In murine models, mebendazole reduced pancreatic tumor initiation, stroma formation, and metastasis, suggesting benefit in both early and late disease.
• Lung and Colorectal Cancer: Oral mebendazole suppressed tumor growth and lung metastases in xenograft models with minimal toxicity.
• Glioblastoma & Brain Tumors: Demonstrated synergy with temozolomide and ionizing radiation, improved survival, and reduced tumor cell proliferation.
• Variety of Cancers: Active in melanoma, breast, thyroid, meningioma, and liver models, including synergy with standard chemotherapy agents.
• Safety: High doses (up to 4g/d) have shown tolerability in GI cancer trials; minimal drug interactions; generally well-tolerated.

Integrative Protocols

• Functional Medicine Use: Incorporated into multi-agent, metabolic protocols for a range of early and advanced solid and hematologic malignancies.
• Compounding & Dosing: 100-200 mg twice daily is a common dose in integrative practice; adjusted to patient context and safety monitoring.

Clinical Considerations

Mebendazole is best viewed as a multi-mechanistic anti-cancer adjunct that aligns with the functional medicine goal of targeting the cancer microenvironment, metabolism, and stem cell populations. It is most effective as part of a combinatorial, individualized regimen under clinical supervision.

References & Published Protocols

• Oncotarget 2021 Johns Hopkins (pancreatic cancer)
• Frontiers Pharmacol 2025 (mechanisms review)
• CancerChoices.org (mechanisms/protocols)
• Oxford Academic (gliomas)

---

For Healthcare Professionals

These materials are for informational and educational use in professional settings. Prescribers are encouraged to review primary literature and consult experienced integrative/functional medicine colleagues prior to initiating therapy. All compounds described remain investigational or off-label for oncologic indications and should be prescribed with patient consent, appropriate monitoring, and as part of a holistic, patient-centered plan.

Brand, Availability & Personalized Compounding

Skip’s Pharmacy stands ready to support your clinic in the safe, evidence-based use of repurposed medications for cancer and chronic disease care.

Empowering Practitioners. Advancing Integrative Cancer Care.

Contact Skip’s Pharmacy to learn more about optimized, protocol-backed access to these therapies for your patients today.

This is for professional informational purposes only. Not intended as patient medical advice. All therapies should be supervised by a qualified healthcare provider.